重庆医学
重慶醫學
중경의학
CHONGQING MEDICAL JOURNAL
2015年
1期
52-54
,共3页
急性冠状动脉综合征%内皮 ,血管%瑞舒伐他汀%经皮冠状动脉介入治疗术%血清炎症因子%预后
急性冠狀動脈綜閤徵%內皮 ,血管%瑞舒伐他汀%經皮冠狀動脈介入治療術%血清炎癥因子%預後
급성관상동맥종합정%내피 ,혈관%서서벌타정%경피관상동맥개입치료술%혈청염증인자%예후
acute coronary syndrome%endothelium,vascular%rosuvastatin%percutaneous coronary intervention%inflammatory fac-tors%prognosis
目的:研究瑞舒伐他汀(RSVT)对急性冠状动脉综合征(ACS)患者行经皮冠状动脉介入治疗术(PCI)后血管内皮功能(VEF)、血清炎症因子(IF)以及预后的影响。方法选择该院2010年7月至2013年7月80例行PCI术的ACS病患进行观察,分为观察组和对照组,每组40例。观察组给予RSVT干预治疗,对照组给予常规治疗。对比两组VEF、IF以及预后情况。结果观察组术后4周VWF为(92.6±12.3)%、ET‐1为(55.6±5.6)ng/L;较对照组术后4周的(105.4±13.6)%、(67.8±7.4)ng/L明显更低;观察组术后4周NO为(78.6±9.4)μmol/L,较对照组术后4周的(63.2±9.5)μmol/L明显更高。观察组PCI术后4周CRP为(5.4±2.2)mg/L,较对照组的(10.5±4.1)mg/L明显更低。观察组CVE发生率为5.00%(2/40)、再狭窄率为2.50%(1/40)明显较对照组的30.00%(12/40)、10.00%(4/40)更低,差异有统计学意义(均P<0.05)。结论RSVT能够有效改善ACS病患PCI术后VEF,减少炎性反应,降低CVE以及再狭窄的发生概率。
目的:研究瑞舒伐他汀(RSVT)對急性冠狀動脈綜閤徵(ACS)患者行經皮冠狀動脈介入治療術(PCI)後血管內皮功能(VEF)、血清炎癥因子(IF)以及預後的影響。方法選擇該院2010年7月至2013年7月80例行PCI術的ACS病患進行觀察,分為觀察組和對照組,每組40例。觀察組給予RSVT榦預治療,對照組給予常規治療。對比兩組VEF、IF以及預後情況。結果觀察組術後4週VWF為(92.6±12.3)%、ET‐1為(55.6±5.6)ng/L;較對照組術後4週的(105.4±13.6)%、(67.8±7.4)ng/L明顯更低;觀察組術後4週NO為(78.6±9.4)μmol/L,較對照組術後4週的(63.2±9.5)μmol/L明顯更高。觀察組PCI術後4週CRP為(5.4±2.2)mg/L,較對照組的(10.5±4.1)mg/L明顯更低。觀察組CVE髮生率為5.00%(2/40)、再狹窄率為2.50%(1/40)明顯較對照組的30.00%(12/40)、10.00%(4/40)更低,差異有統計學意義(均P<0.05)。結論RSVT能夠有效改善ACS病患PCI術後VEF,減少炎性反應,降低CVE以及再狹窄的髮生概率。
목적:연구서서벌타정(RSVT)대급성관상동맥종합정(ACS)환자행경피관상동맥개입치료술(PCI)후혈관내피공능(VEF)、혈청염증인자(IF)이급예후적영향。방법선택해원2010년7월지2013년7월80례행PCI술적ACS병환진행관찰,분위관찰조화대조조,매조40례。관찰조급여RSVT간예치료,대조조급여상규치료。대비량조VEF、IF이급예후정황。결과관찰조술후4주VWF위(92.6±12.3)%、ET‐1위(55.6±5.6)ng/L;교대조조술후4주적(105.4±13.6)%、(67.8±7.4)ng/L명현경저;관찰조술후4주NO위(78.6±9.4)μmol/L,교대조조술후4주적(63.2±9.5)μmol/L명현경고。관찰조PCI술후4주CRP위(5.4±2.2)mg/L,교대조조적(10.5±4.1)mg/L명현경저。관찰조CVE발생솔위5.00%(2/40)、재협착솔위2.50%(1/40)명현교대조조적30.00%(12/40)、10.00%(4/40)경저,차이유통계학의의(균P<0.05)。결론RSVT능구유효개선ACS병환PCI술후VEF,감소염성반응,강저CVE이급재협착적발생개솔。
Objective To study the effect of rosuvastatin(RSVT) on the vascular endothelial function(VEF) ,inflammatory fac‐tors(IF) and prognosis in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention(PCI) .Methods Eighty cases of ACS patients with PCI in our hospital selected from July 2010 to July 2013 were randomly divided into observed group and control group ,40 cases in each group .The observation group were given interference treatment with RSVT while the control group received conventional treatment .The VEF ,IF and prognosis were compared between groups .Results The VWF at 4 weeks after PCI in observation group was lower than that in control group [(92 .6 ± 12 .3)% vs .(105 .4 ± 13 .6)% ,P<0 .05];The ET‐1 at 4 weeks after PCI in observation group was lower than that in control group[(55 .6 ± 5 .6)ng/L vs .(67 .8 ± 7 .4)ng/L ,P<0 .05] .The NO at 4 weeks after PCI in observation group was higher than that of control group[(78 .6 ± 9 .4)μmol/L vs .(63 .2 ± 9 .5)μmol/L ,P<0 .05] .The CRP at 4 weeks after PCI in observation group was lower than that in control group[(5 .4 ± 2 .2) mg/L vs .(10 .5 ± 4 .1)mg/L ,P<0 .05] .The incidence of CVE was 5 .00% (2/40) ,restenosis rate was 2 .50% (1/40) in observa‐tion group ,which was significantly lower than those of the control group [30 .00% (12/40) ,10 .00% (4/40)] ,the differences were statistically significant(P<0 .05) .Conclusion RSVT could effectively improve the VEF and reduce inflammation ,CVE and rest‐enosis rate in patients with ACS after PCI .